Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Trevi Therapeutics, Inc.TRVI · Entity 4387 | Director | June 03, 2026 | June 04, 2026 |
| Vericel CorpVCEL · Entity 4481 | Director · President and CEO | February 24, 2026 | February 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Trevi Therapeutics, Inc.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Nonstatutory Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.45 · Expires 2036-06-02 | Direct | 35,000 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 35,000 · Balance 35,000 F1: This option was granted on June 3, 2026. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 3, 2026. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer.
Vericel Corp
Report date February 24, 2026 · Filed February 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 303,020 |
Reported balance
After 2026-02-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-24 · Exercise / conversion · Acquired 18,250 · Balance 303,020 F1: The Restricted Stock Units (RSUs) converted to phantom stock units and are deferred under the Vericel Corporation Deferred Compensation Plan. The units will be payable only in shares of Common Stock upon the Reporting Person's elected Benefit Distribution Date. F2: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 22, 2024, the Reporting Person deferred the receipt of 18,250 shares of Common Stock and instead received 18,250 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. F3: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| Common StockSEC Table I · non-derivative | Direct | 321,270 |
Reported balance
After 2026-02-24 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-02-24 · Exercise / conversion · Acquired 18,250 · Balance 321,270 F4: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively. F3: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| Common StockSEC Table I · non-derivative | Direct | 312,446 |
Reported balance
After 2026-02-24 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-02-24 · Tax withholding · Disposed 8,824 · Balance 312,446 F5: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. F3: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 36,500 |
Reported balance
After 2026-02-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-24 · Exercise / conversion · Acquired 18,250 · Balance 36,500 F6: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F2: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 22, 2024, the Reporting Person deferred the receipt of 18,250 shares of Common Stock and instead received 18,250 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. F7: No expiration date for this type of award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 54,750 |
Reported balance
After 2026-02-24 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-24 · Exercise / conversion · Acquired 18,250 · Balance 54,750 F6: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F8: The Fair Market Value of the vested derivative securities is $38.09 per share. F4: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively. F7: No expiration date for this type of award. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units (RSUs) converted to phantom stock units and are deferred under the Vericel Corporation Deferred Compensation Plan. The units will be payable only in shares of Common Stock upon the Reporting Person's elected Benefit Distribution Date.
F2: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 22, 2024, the Reporting Person deferred the receipt of 18,250 shares of Common Stock and instead received 18,250 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan.
F3: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F4: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively.
F5: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs.
F6: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.
F7: No expiration date for this type of award.
F8: The Fair Market Value of the vested derivative securities is $38.09 per share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2026 Filed Jun 4, 2026 20:05 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | GrantNonstatutory Stock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $13.45 | $0.00 |
DisclosureSEC source: 0001193125-26-257370 · ownership.xml · derivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2036-06-02 F1 · derivative.exercise_date: This option was granted on June 3, 2026. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 18,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-26-006974 · form4.xml · derivative · entry 5 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,750 Underlying: Common Stock · 18,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F8 · price: The Fair Market Value of the vested derivative securities is $38.09 per share. F4 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively. F7 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 18,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-26-006974 · form4.xml · derivative · entry 4 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,500 Underlying: Common Stock · 18,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F2 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 22, 2024, the Reporting Person deferred the receipt of 18,250 shares of Common Stock and instead received 18,250 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. F2 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 22, 2024, the Reporting Person deferred the receipt of 18,250 shares of Common Stock and instead received 18,250 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. F7 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Tax withholdingCommon Stock | 8,824 | $38.09 | $336,106.16 |
DisclosureSEC source: 0001140361-26-006974 · form4.xml · nonDerivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 312,446 F5 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. F3 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 18,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-006974 · form4.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 321,270 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively. F3 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 18,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-26-006974 · form4.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 303,020 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Restricted Stock Units (RSUs) converted to phantom stock units and are deferred under the Vericel Corporation Deferred Compensation Plan. The units will be payable only in shares of Common Stock upon the Reporting Person's elected Benefit Distribution Date. F2 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 22, 2024, the Reporting Person deferred the receipt of 18,250 shares of Common Stock and instead received 18,250 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. F3 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 21:06 UTC | Vericel Corp VCEL · Entity 4481 | GrantRestricted Stock Unit · Derivative | 73,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-006314 · form4.xml · derivative · entry 7 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,000 Underlying: Common Stock · 73,000 shares Expires not disclosed F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F10 · derivative.exercise_date: These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 19, 2027. The remaining RSUs will vest in annual installments on February 19, 2028, February 19, 2029, and February 19, 2030, respectively. F7 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 21:06 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (Right to Buy) · Derivative | 182,500 | $0.00 Strike: $38.17 | $0.00 |
DisclosureSEC source: 0001140361-26-006314 · form4.xml · derivative · entry 6 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,500 Underlying: Common Stock · 182,500 shares Expires 2036-02-19 F9 · derivative.exercise_date: These options shall begin vesting on February 19, 2026 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 11,700 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-26-006314 · form4.xml · derivative · entry 5 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F8 · price: The Fair Market Value of the vested derivative securities is $37.41 per share. F4 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 18, 2022. F7 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 18,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-26-006314 · form4.xml · derivative · entry 4 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,250 Underlying: Common Stock · 18,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F2 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 17, 2023. The remaining RSUs will vest on February 17, 2027. Upon the vesting of RSUs granted to the Reporting Person on February 17, 2023, the Reporting Person deferred the receipt of 18,250 shares of Common Stock and instead received 18,250 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. F2 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 17, 2023. The remaining RSUs will vest on February 17, 2027. Upon the vesting of RSUs granted to the Reporting Person on February 17, 2023, the Reporting Person deferred the receipt of 18,250 shares of Common Stock and instead received 18,250 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. F7 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:06 UTC | Vericel Corp VCEL · Entity 4481 | Tax withholdingCommon Stock | 5,657 | $37.41 | $211,628.37 |
DisclosureSEC source: 0001140361-26-006314 · form4.xml · nonDerivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 284,770 F5 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. F3 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 11,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-006314 · form4.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 290,427 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 18, 2022. F3 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 18,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-26-006314 · form4.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 278,727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Restricted Stock Units (RSUs) converted to phantom stock units and are deferred under the Vericel Corporation Deferred Compensation Plan. The units will be payable only in shares of Common Stock upon the Reporting Person's elected Benefit Distribution Date. F2 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 17, 2023. The remaining RSUs will vest on February 17, 2027. Upon the vesting of RSUs granted to the Reporting Person on February 17, 2023, the Reporting Person deferred the receipt of 18,250 shares of Common Stock and instead received 18,250 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. F3 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 30, 2025 Filed Feb 13, 2026 21:05 UTC | Vericel Corp VCEL · Entity 4481 | GrantCommon Stock | 123 | $36.17 | $4,448.91 |
DisclosureSEC source: 0001140361-26-005418 · form5.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 260,477 F1 · shares: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:00 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | GrantNonstatutory Stock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $6.25 | $0.00 |
DisclosureSEC source: 0000950170-25-086112 · ownership.xml · derivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2035-06-10 F1 · derivative.exercise_date: This option was granted on June 11, 2025. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer. Read SEC document |
| May 15, 2025 Filed May 16, 2025 20:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,063 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001140361-25-019474 · form4.xml · derivative · entry 6 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,063 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 6.25% of these options, representing the right to purchase a total of 90,000 shares, became exercisable immediately on May 22, 2017. An additional 6.25% became exercisable on August 8, 2017 and continued to vest in equal quarterly installments from August 8, 2017, contingent upon continued service to the Company. F4 · derivative.expiration_date: These options, which were awarded on May 22, 2017, would otherwise expire and become forfeitable on May 22, 2027. Read SEC document |
| May 15, 2025 Filed May 16, 2025 20:06 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 14,063 | $41.53 | $584,036.39 |
DisclosureSEC source: 0001140361-25-019474 · form4.xml · nonDerivative · entry 4 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 260,354 F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2024. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| May 15, 2025 Filed May 16, 2025 20:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 14,063 | $2.65 | $37,266.95 |
DisclosureSEC source: 0001140361-25-019474 · form4.xml · nonDerivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 274,417 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,062 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001140361-25-019474 · form4.xml · derivative · entry 5 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,063 Underlying: Common Stock · 14,062 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 6.25% of these options, representing the right to purchase a total of 90,000 shares, became exercisable immediately on May 22, 2017. An additional 6.25% became exercisable on August 8, 2017 and continued to vest in equal quarterly installments from August 8, 2017, contingent upon continued service to the Company. F4 · derivative.expiration_date: These options, which were awarded on May 22, 2017, would otherwise expire and become forfeitable on May 22, 2027. Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:06 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 14,062 | $42.25 | $594,119.50 |
DisclosureSEC source: 0001140361-25-019474 · form4.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 260,354 F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2024. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 14,062 | $2.65 | $37,264.30 |
DisclosureSEC source: 0001140361-25-019474 · form4.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 274,416 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 24,850 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001140361-25-013471 · form4.xml · derivative · entry 6 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,850 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase 210,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 8, 2017, which was one quarter after the date on which the option was granted. F4 · derivative.expiration_date: These options, which were awarded on February 8, 2017, would otherwise expire and become forfeitable on February 8, 2027. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 24,850 | $41.89 | $1,040,966.50 |
DisclosureSEC source: 0001140361-25-013471 · form4.xml · nonDerivative · entry 4 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 260,354 F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2024. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 24,850 | $2.75 | $68,337.50 |
DisclosureSEC source: 0001140361-25-013471 · form4.xml · nonDerivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 285,204 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 09, 2025 Filed Apr 11, 2025 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 24,850 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001140361-25-013471 · form4.xml · derivative · entry 5 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,850 Underlying: Common Stock · 24,850 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase 210,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 8, 2017, which was one quarter after the date on which the option was granted. F4 · derivative.expiration_date: These options, which were awarded on February 8, 2017, would otherwise expire and become forfeitable on February 8, 2027. Read SEC document |
| April 09, 2025 Filed Apr 11, 2025 20:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 24,850 | $41.11 | $1,021,583.50 |
DisclosureSEC source: 0001140361-25-013471 · form4.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 260,354 F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2024. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 09, 2025 Filed Apr 11, 2025 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 24,850 | $2.75 | $68,337.50 |
DisclosureSEC source: 0001140361-25-013471 · form4.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 285,204 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| March 13, 2025 Filed Mar 14, 2025 20:07 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 26,592 | $0.00 Strike: $1.95 | $0.00 |
DisclosureSEC source: 0001140361-25-008820 · form4.xml · derivative · entry 6 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,592 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase 165,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 9, 2016, which was one quarter after the date on which the option was granted. F4 · derivative.expiration_date: These options, which were awarded on February 9, 2016, would otherwise expire and become forfeitable on February 9, 2026. Read SEC document |
| March 13, 2025 Filed Mar 14, 2025 20:07 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 26,592 | $45.78 | $1,217,381.76 |
DisclosureSEC source: 0001140361-25-008820 · form4.xml · nonDerivative · entry 4 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 259,997 F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2024. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| March 13, 2025 Filed Mar 14, 2025 20:07 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 26,592 | $1.95 | $51,854.40 |
DisclosureSEC source: 0001140361-25-008820 · form4.xml · nonDerivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 286,589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 20:07 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 26,591 | $0.00 Strike: $1.95 | $0.00 |
DisclosureSEC source: 0001140361-25-008820 · form4.xml · derivative · entry 5 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,592 Underlying: Common Stock · 26,591 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase 165,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 9, 2016, which was one quarter after the date on which the option was granted. F4 · derivative.expiration_date: These options, which were awarded on February 9, 2016, would otherwise expire and become forfeitable on February 9, 2026. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 20:07 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 26,591 | $46.31 | $1,231,429.21 |
DisclosureSEC source: 0001140361-25-008820 · form4.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 259,997 F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2024. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 20:07 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 26,591 | $1.95 | $51,852.45 |
DisclosureSEC source: 0001140361-25-008820 · form4.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 286,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 18,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-25-006085 · form4.xml · derivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,750 Underlying: Common Stock · 18,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F6 · price: The Fair Market Value of the vested derivative securities is $52.33 per share. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest in annual installments on February 22, 2026, February 22, 2027, and February 22, 2028, respectively. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Tax withholdingCommon Stock | 8,459 | $52.33 | $442,659.47 |
DisclosureSEC source: 0001140361-25-006085 · form4.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 259,997 F3 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 18,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-006085 · form4.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 268,456 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest in annual installments on February 22, 2026, February 22, 2027, and February 22, 2028, respectively. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | GrantRestricted Stock Unit · Derivative | 73,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-005656 · form4.xml · derivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,000 Underlying: Common Stock · 73,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 20, 2026. The remaining RSUs will vest in annual installments on February 20, 2027, February 20, 2028, and February 20, 2029, respectively. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (Right to Buy) · Derivative | 182,500 | $0.00 Strike: $54.31 | $0.00 |
DisclosureSEC source: 0001140361-25-005656 · form4.xml · derivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,500 Underlying: Common Stock · 182,500 shares Expires 2035-02-20 F1 · derivative.exercise_date: These options shall begin vesting on February 20, 2025 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 19, 2025 Filed Feb 20, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 8,938 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-25-005255 · form4.xml · derivative · entry 8 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,938 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F10 · price: The Fair Market Value of the vested derivative securities is $57.78 per share. F6 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 19, 2021. F8 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 19, 2025 Filed Feb 20, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Tax withholdingCommon Stock | 4,196 | $57.78 | $242,444.88 |
DisclosureSEC source: 0001140361-25-005255 · form4.xml · nonDerivative · entry 5 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,206 F5 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. F3 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 19, 2025 Filed Feb 20, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 8,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-005255 · form4.xml · nonDerivative · entry 4 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 254,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 19, 2021. F3 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 11,700 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-25-005255 · form4.xml · derivative · entry 7 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,700 Underlying: Common Stock · 11,700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F9 · price: The Fair Market Value of the vested derivative securities is $57.28 per share. F4 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 18, 2022. The remaining RSUs will vest on February 18, 2026. F8 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 18,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-25-005255 · form4.xml · derivative · entry 6 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,500 Underlying: Common Stock · 18,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F2 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 17, 2023. The remaining RSUs will vest in annual installments on February 17, 2026, and February 17, 2027, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 17, 2023, the Reporting Person deferred the receipt of 18,250 shares of Common Stock and instead received 18,250 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. F2 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 17, 2023. The remaining RSUs will vest in annual installments on February 17, 2026, and February 17, 2027, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 17, 2023, the Reporting Person deferred the receipt of 18,250 shares of Common Stock and instead received 18,250 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. F8 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Tax withholdingCommon Stock | 5,423 | $57.28 | $310,629.44 |
DisclosureSEC source: 0001140361-25-005255 · form4.xml · nonDerivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 245,464 F5 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. F3 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 11,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-005255 · form4.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,887 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 18, 2022. The remaining RSUs will vest on February 18, 2026. F3 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 18,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-25-005255 · form4.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Restricted Stock Units (RSUs) converted to phantom stock units and are deferred under the Vericel Corporation Deferred Compensation Plan. The units will be payable only in shares of Common Stock upon the Reporting Person's elected Benefit Distribution Date. F2 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 17, 2023. The remaining RSUs will vest in annual installments on February 17, 2026, and February 17, 2027, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 17, 2023, the Reporting Person deferred the receipt of 18,250 shares of Common Stock and instead received 18,250 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. F3 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| November 14, 2024 Filed Nov 15, 2024 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $3.02 | $0.00 |
DisclosureSEC source: 0001140361-24-047069 · form4.xml · derivative · entry 6 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase 440,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on April 5, 2015, which was one quarter after the date on which the option was granted. F4 · derivative.expiration_date: These options, which were awarded on January 5, 2015, would otherwise expire and become forfeitable on January 5, 2025. Read SEC document |
| November 14, 2024 Filed Nov 15, 2024 21:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 17,500 | $53.93 | $943,775.00 |
DisclosureSEC source: 0001140361-24-047069 · form4.xml · nonDerivative · entry 4 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 220,937 F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 1, 2023. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| November 14, 2024 Filed Nov 15, 2024 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 17,500 | $3.02 | $52,850.00 |
DisclosureSEC source: 0001140361-24-047069 · form4.xml · nonDerivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 238,437 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $3.02 | $0.00 |
DisclosureSEC source: 0001140361-24-047069 · form4.xml · derivative · entry 5 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase 440,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on April 5, 2015, which was one quarter after the date on which the option was granted. F4 · derivative.expiration_date: These options, which were awarded on January 5, 2015, would otherwise expire and become forfeitable on January 5, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.